Progress in Stroke and Preeclampsia Programs
Solid progress reported on stroke and preeclampsia programs, with 2025 expected to be transformative. Key sites in the AIS study are being activated, with contracts signed and site initiation visits scheduled. The preeclampsia program has secured regulatory approval in South Africa, and the first participant was enrolled.
Protocol Updates to Accelerate Enrollment
ReMEDy2 protocol updates include inclusion of thrombolytic nonresponders and an increase in interim analysis sample size from 144 to 200 participants. These changes aim to accelerate enrollment rates by 50% to 100% and improve overall response rates.
Financial Position and Cash Runway
As of September 30, 2024, the company has $50.2 million in cash, cash equivalents, and investments, providing a financial runway to Q3 2026.